These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24103788)

  • 1. Modelling olanzapine-induced weight gain in rats.
    van der Zwaal EM; Janhunen SK; la Fleur SE; Adan RA
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):169-86. PubMed ID: 24103788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.
    Deng C; Lian J; Pai N; Huang XF
    J Psychopharmacol; 2012 Sep; 26(9):1271-9. PubMed ID: 22695490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.
    Skrede S; Martins L; Berge RK; Steen VM; López M; Fernø J
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):91-104. PubMed ID: 23919889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.
    Liebig M; Gossel M; Pratt J; Black M; Haschke G; Elvert R; Juretschke HP; Neumann-Haefelin C; Kramer W; Herling AW
    Obesity (Silver Spring); 2010 Oct; 18(10):1952-8. PubMed ID: 20168311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats.
    Lazzari P; Serra V; Marcello S; Pira M; Mastinu A
    Eur Neuropsychopharmacol; 2017 Jul; 27(7):667-678. PubMed ID: 28377074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.
    Shobo M; Yamada H; Mihara T; Kondo Y; Irie M; Harada K; Ni K; Matsuoka N; Kayama Y
    Behav Brain Res; 2011 Jan; 216(2):561-8. PubMed ID: 20816897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of thermogenesis in antipsychotic drug-induced weight gain.
    Stefanidis A; Verty AN; Allen AM; Owens NC; Cowley MA; Oldfield BJ
    Obesity (Silver Spring); 2009 Jan; 17(1):16-24. PubMed ID: 19107124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased lean body mass as an early indicator of olanzapine-induced weight gain in healthy men.
    Daurignac E; Leonard KE; Dubovsky SL
    Int Clin Psychopharmacol; 2015 Jan; 30(1):23-8. PubMed ID: 25350366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.
    Cooper GD; Harrold JA; Halford JC; Goudie AJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):428-36. PubMed ID: 17933447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
    Gothelf D; Falk B; Singer P; Kairi M; Phillip M; Zigel L; Poraz I; Frishman S; Constantini N; Zalsman G; Weizman A; Apter A
    Am J Psychiatry; 2002 Jun; 159(6):1055-7. PubMed ID: 12042200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine and weight gain.
    Isaac MB; Isaac MT
    Am J Psychiatry; 2005 Sep; 162(9):1764-5; author reply 1765. PubMed ID: 16135655
    [No Abstract]   [Full Text] [Related]  

  • 12. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.
    van der Zwaal EM; Luijendijk MC; Adan RA; la Fleur SE
    Eur J Pharmacol; 2008 May; 585(1):130-6. PubMed ID: 18378227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
    Raskind MA; Burke BL; Crites NJ; Tapp AM; Rasmussen DD
    Neuropsychopharmacology; 2007 Feb; 32(2):284-8. PubMed ID: 16710316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.
    Belanoff JK; Blasey CM; Clark RD; Roe RL
    Diabetes Obes Metab; 2010 Jun; 12(6):545-7. PubMed ID: 20518810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment.
    Lian J; Huang XF; Pai N; Deng C
    PLoS One; 2014; 9(8):e104160. PubMed ID: 25084453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways.
    Lian J; Huang XF; Pai N; Deng C
    Psychoneuroendocrinology; 2014 Oct; 48():77-86. PubMed ID: 24992721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.
    Fell MJ; Marshall KM; Williams J; Neill JC
    J Psychopharmacol; 2004 Jun; 18(2):149-55. PubMed ID: 15260902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.
    Belanoff JK; Blasey CM; Clark RD; Roe RL
    Eur J Pharmacol; 2011 Mar; 655(1-3):117-20. PubMed ID: 21269600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
    Han M; Deng C; Burne TH; Newell KA; Huang XF
    Psychoneuroendocrinology; 2008 Jun; 33(5):569-80. PubMed ID: 18358632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.
    Minet-Ringuet J; Even PC; Goubern M; Tomé D; de Beaurepaire R
    Appetite; 2006 May; 46(3):254-62. PubMed ID: 16551485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.